On September 28, 2020, new rules for determining the maximum size of wholesale and retail markups to the actual selling prices of manufacturers of medicines included in the vital and essential drugs list came into force.
On September 8, 2020, the Administrative Regulations of the Federal Service for Surveillance in Healthcare on the provision of state services for issuing a permit for the retail sale of medicinal products for medical use remotely, approved by order of the Federal Service for Surveillance in Healthcare N 5161 (hereinafter referred to as the “Administrative Regulations”), came into force.
Decree of the Government of Russia dated July 4, 2020 N 982 establishes that from January 1, 2021, such legal acts as:
On August 31, 2020, the decree of the Ministry of Health of the Russian Federation of May 15, 2020, N 450n “On approval of the procedure for determining the initial (maximum) contract price, the price of a contract concluded with a single supplier (contractor, performer), and the initial unit price of goods” came into force, work, services in the procurement of medical products.
By the Decree of the Government of Russia dated June 30, 2020 N 955, the order of the introduction into the circulation of medicinal products for medical use until January 1, 2021, were approved.
- The Ministry of Health has developed a procedure for maintaining a register of citizens entitled to subsidized medicines
- Supervision over the circulation of medicinal products and medical devices have been included in the experiment on pre-trial online appeal of decisions of control authorities
- Federal Law No. 206-FZ of July 13, 2020 amended the legislation on the provision of citizens with medicines, medical devices and specialized health food products
- Liability for non-repatriation of foreign currency earnings has been changed